Unimpeded opportunity for all Americans is essential to our economic and political prosperity. To retain hegemony in bringing new products and services to the marketplace both in the U.S. and abroad, franchise systems continue to provide the widest possible entrepreneurial opportunities for everyone. Los Angeles-based Giggles N’ Hugs, Inc. (OTCQB: GIGL) is a first-of-its-kind, award-winning family restaurant and play space that combines organic, gourmet food and exciting play elements for children, with a 2,500-square-foot play space in the middle of its restaurants.

The concept is similar to Chuck E. Cheese, but offers a healthier, high-end version for health conscious parents and families. Parents eat and relax, while the kids have an incredible time playing in the custom-made play area, which is loaded with giant climbers, dragons, castles, pirate ships slides and swings and a multitude of other toys.

Revenue is derived from several sources, including food and beverage sales, beer and wine, birthday parties (40 percent), admission and membership fees, and retail sales. These revenue-generating locations are also highly sought-after tenants. The company currently has three locations in some of the premier malls around Los Angeles, and four of the largest mall owners in the country have offered Giggles N’ Hugs up to 75 percent discounts on rent and upward of $700,000 of upfront cash for each location in order to get Giggles N’ Hugs into their properties located around the country.

In other words, the proof is in the ‘organic bread pudding’ with the concept Giggles N’ Hugs has created. The company has taken a successful business model (i.e. Chuck E. Cheese) and adapted it to today’s health conscience consumer with its organic menu items. It’s essential to appeal to as many audiences as possible when providing products and services. Giggles N’ Hugs has forged a perfect marriage, so to speak, with its ‘kid friendly’ birthday party atmosphere and delicious menu, allowing it to appeal to nearly every demographic.

Learn more by visiting www.gigglesnhugs.com

Let us hear your thoughts: Giggles ‘N Hugs, Inc. Message Board

Propanc Health Group Corp. (OTCQB: PPCH) is an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients suffering from solid tumors, such as those resulting from pancreatic, ovarian, and colorectal cancers. The company recently announced results from studies for its lead product, PRP, confirming a synergistic response to a broad range of cancer indications, including kidney, melanoma, brain, prostate, liver, uterine and lung cancers. The data provides compelling evidence that PRP has the potential to fight a broad range of cancer types, some with significant unmet medical needs. The company will continue to investigate PRP’s efficacy in these indications through clinical trials.

Moreover, data from the recent cell line studies tested at the R&D facility of Propanc’s contract research partner, vivoPharm LLC, which is headquartered in Hershey, Pennsylvania, showed a synergistic response between the two active components, trypsinogen and chymotrypsinogen, further strengthening its lead patent claims in key jurisdictions throughout North America and Europe.

The company has also confirmed a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, currently scheduled for the end of April. The purpose of the meeting is to discuss Propanc’s ongoing development activities for PRP, including preparation and structure of animal safety/toxicology studies and its proposed early stage patient trials, together with supporting activities.

Propanc has developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Its products involve or employ proenzymes, which are inactive precursors of enzymes.

Learn more by visiting www.propanc.com

Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) scored a birdie at the recent Orlando PGA Merchandise Show, which came to a close on January 29, 2016. The company received orders of more than $250,000 and follow on commitments exceeding $20,575,000 for its Pro Series Lithium Ion Golf Car battery systems. These large format golf cart batteries were launched at this same Professional Golfers’ Association (PGA) show in Orlando, Florida, back in January 2015. No doubt, the size of Oakridge’s order book is a sign of things to come in the lithium industry.

A research report published by Goldman Sachs in December 2015, titled ‘What if I Told you… Themes, Dreams and Flying Machines’, proclaims ‘Lithium is the new gasoline’. The report states that the confluence of technological innovation, government support and public embrace of green technologies will increase electric vehicle (EV) penetration from three percent now to 22 percent in 10 years’ time. The automotive industry will, undoubtedly, have its eyes on companies like Oakridge to see how the Pro Series performs, because the golf carts it will power may be considered a type of battery electric vehicle (BEV), like the Nissan (OTC: NSANY) Leaf, the Fiat (NYSE: FCAU) 500e or the Tesla (NASDAQ: TSLA) Model S. This market development in EVs is expected to invigorate the entire lithium industry.

The Goldman Sachs analysts are not the only ones that see upbeat prospects for lithium. The industry analysts at Japanese research firm Taiyou Research surmise that ‘the global market for lithium ion batteries is a fast growing one and is expected to cross $30 billion by 2020’. At present, lithium ion batteries are mostly found in consumer electronic devices, but with the advent of cells of greater capacity and power in large-format applications, their use in EVs and storage applications is increasing. Both capacity and power are important factors in batteries and, depending on the application, one takes precedence to the other. These characteristics can be examined by comparing them to containers. A 2-liter bottle has a large volume and a small mouth, similar to a high-energy low-power system. A 1 lb. marmalade jar, on the other hand, has small volume but a large mouth, similar to a low-energy high-power system.

Oakridge manufactures both high-energy low-power systems and low-energy high-power systems. Its Pro Series, which has been such a big hit at the PGA show, is a high-energy low-power battery. The Pro Series comes in four capacities, measured in ampere-hours (Ah) – including 40 Ah, 60 Ah, 100 Ah and 160 Ah – all of which have a recommended voltage limit for discharge of 12 volts. At that discharge rate, the Pro Series 40Ah is expected to provide energy enough for at least 20 miles. The Pro Series 60Ah will provide enough energy for 30 miles; the Pro Series 100Ah will reach 55 miles; and the Pro Series 160Ah will get to 90 miles or more. The Pro Series is designed to be a good caddy, giving you 12 to 16 rounds per charge.

Oakridge Global Energy Solutions is holding the course with pro golfers, and now it’s planning on joining the easy riders. A commercial introduction of the Liberty Series Lithium Ion motorcycle battery is planned for the 75th anniversary of the Daytona Beach Bike Week, which runs from March 4 – 13, 2016. Oakridge’s Liberty Series is an example of a low-energy high-power battery that is required in starting, lighting and ignition (SLI) systems.

For more information, visit www.oakridgeglobalenergy.com

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

OurPet’s Company’s (OTCQX: OPCO) business strategies have contributed substantially to its success, and so has the growth of the pet products industry. The pet products industry is booming. It has grown from around $16 billion in annual sales in 1995, when OurPet’s first entered the industry, to around $65 billion in 2015, according to the American Pet Products Association.

In a February 2016 interview with Thomas Rice, editor of The Bowser Report, Dr. Steve Tsengas, CEO of OurPet’s Company, shared his insights about the future of his company and the pet products industry. “The industry continues to grow, especially cat products, which are increasing about 6% a year,” according to Dr. Tsengas. He also shared that the annual sales number for dog products is increasing at around 2-3%.

OurPet’s specializes in providing easy-to-use feeding and waste management solutions for both dogs and cats. Dr. Tsengas’s life-long interest in holistic health, combined with his love of pets, led him to pursue a PhD in natural health and nutrition. That drive also led him to apply his knowledge and interest to developing pet accessories and consumable products that improve the health, safety, comfort and enjoyment of pets. Dr. Tsengas has had a deep interest in a holistic, integrated approach to health for more than 35 years, and, to date, his unique and novel pet products have been issued dozens of patents.

OurPet’s product design process begins with an analysis of the health, behavioral and lifestyle needs of a pet and its respective pet parent(s). Once the company discovers an innovative way to fulfill those needs, it offers a problem-solving solution to the pet owner(s). Over the years, this approach has resulted in the creation of highly-marketable products that are now being offered to retailers.

These days, OurPet’s is preparing for its next stage of growth. Management hopes that will mean about $50 million in annual revenues five years from now, and, as a result, the team has updated the company’s infrastructure to handle a higher sales volume. As Dr. Tsengas explained, the company has automated its “Enterprise Resource Planning system complete with automatic warehouse logistics” and it is now receiving and processing orders electronically, all the way to payment. At the end of 2015, OurPet’s also finalized a new branding strategy. Now, the company has two brands: The OurPets® brand caters to pet specialty markets like PetSmart and Petco and the Pet Zone® brand caters to mass markets like Walmart. With these marketing and technical initiatives in place, OurPet’s appears poised for long-term growth and success.

For the full interview, visit http://dtn.fm/q3DjP

For more information, visit the company’s website at www.ourpets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Vapor Corp. (OTC: VPCO) is a U.S. based distributor and retailer of vaporizers, e-liquids and electronic cigarettes. It recently acquired the retail chain “The Vape Store” as part of a merger with Vaporin, Inc. The company’s innovative technology enables users to inhale nicotine vapor without smoke, tar, ash or carbon monoxide. The company’s brands include VaporX®, Krave®, Hookah Stix® and Vaporin™ and are distributed to retail stores throughout the U.S. and Canada. The company sells direct to consumers via e-commerce and company-owned brick-and-mortar retail locations operating under “The Vape Store” brand.

With a number of trademarked products, Vapor Corp. is consistently preparing to commercialize additional products. The company is developing new flavor profiles that are distinct to its brands. Management believes that as the electronic cigarette industry matures, users of electronic cigarettes will develop preferences for the product based not only on quality, ability to successfully deliver nicotine, battery capacity, and smoke volume generated, but also on taste and flavor, as smokers do with their preferred brand of conventional tobacco cigarettes.

Vapor Corp. has a patent pending for a soft-tip electronic cigarette filter, which more closely resembles the tactile experience of a traditional tobacco cigarette in a user’s mouth. In addition, the company holds rights to a patent pending for the first electronic cigarette that can be recharged by shaking the product. This technology may eventually allow for continued use without having to recharge the electronic cigarette by plugging it into an electrical outlet.

In addition, Vapor Corp. has a patent pending on a new configuration for the airflow sensors currently used in electronic cigarettes. The new configuration will allow the battery to be sealed to enhance the reliability and performance of the electronic cigarette.

Learn more by visiting www.vapor-corp.com

Nutra Pharma Corporation (OTCQB: NPHC) is actively pursuing growth plans that will bolster its core business while expanding its reach into vital commercial markets. A versatile biotechnology company, Nutra Pharma markets Nyloxin and Pet Pain-Away (homeopathic drugs that treat moderate-to-severe chronic pain in humans and pets, respectively) to the over-the-counter pain management market.

Millions of Americans suffer from persistent pain. From veterans to active-duty military personnel to civilians, the presence of chronic pain is a major factor in many lives and so is the search for a lasting cure. This is where Nutra Pharma comes in.

The company has developed pain-relief solutions that are both potent and long-lasting. They are non-opiate, non-narcotic and non-addictive. They are safe for vital organs, such as the stomach, liver and kidney, and they do not affect cognitive or motor skills unfavorably. By offering pain-relief solutions that counter the record levels of opioid abuse evidenced in society, as well as the dangers of abusing acetaminophen and non-steroidal anti-inflammatory drugs such as ibuprofen, Nutra Pharma is poised to impact a vast, global market and benefit from the resulting rewards.

With the recent expansion of its key personnel, including the addition of Tom Northrop as senior commercial development officer, Nutra Pharma is facing several promising stages of growth. Northrop is a member of Tri-State Capital Partners, a New York-based management advisory and investment firm that advises promising enterprises, and his involvement with Nutra Pharma signals Tri-State’s involvement as well.

Tri-State’s support comes part-and-parcel with management resources, strategy development and implementation expertise and capital funding knowledge. With this level of support, Nutra Pharma has the tools that will allow for its expansion into new markets, including an opportunity to spearhead novel marketing and promotional activities geared toward the elderly, aging athletes and healthcare, governmental and military entities. The company will also have an opening to focus on the completion of its scientifically-rigorous pain relief trials in multiple locations.

That is only the beginning. With Tri-State’s backing, Nutra Pharma will also have the resources to accelerate the development of its prescription drug candidates. Presently, the company is designing and developing treatments for multiple sclerosis, human immunodeficiency virus and adrenomyeloneuropath.

For more information on the company, visit www.NutraPharma.com

Let us hear your thoughts: Nutra Pharma Corp. Message Board

Based in Shenzhen, China, Moxian, Inc. (OTCQB: MOXC) provides social marketing and other promotional platforms for companies who want to showcase their businesses through social media. These companies are able to see consumer trends through compiled data from Moxian’s proprietary Social Customer Relationship Management (SCRM) system. Businesses can then run advertising campaigns that target specific users. Moxian retains these consumers through incentives such as points and prizes on their own Moxian+ (User) app.

The Moxian+ (User) app allows users to instantly receive information about nearby merchants and any promotions or events they’re offering. They can also play fun games and collect MO-Coins and MO-Points that transfer globally to any business within the Moxian system. The app provides a Messenger service so that users can easily communicate with friends or continue to build their social networks. Consumers are then enticed to cash in their coins at a virtual mall, where gifts are sponsored by both Moxian and participating merchants.

The social media platform itself is called Weibo and can be accessed from anywhere. The site offers links to information such as celebrity news, fitness, movies, food, and health. There’s also a feed where users can keep up with current news stories, local activities, and people. Consumers can then play a variety of games through Weibo, including poker and soccer or role-playing games (RPG) like Stone Age or Brave Covenant. After they collect enough coins from their wins, users cash in at the Points Mall, where they can buy more games, smart watches, keyboards, mouse pads, plush toys and more.

Fun games and a point-incentive system could increase retention for any company. Plus, participating merchants can continuously advertise their businesses through Moxian’s Weibo, sponsored prizes, and the app, gaining even more exposure. Consumers and businesses can achieve the coveted, “online lifestyle, offline fun” relationship. Moxian intends to keep that relationship healthy by successfully offering a platform for merchants and consumers to meet and benefit from each other.

For more information, visit the company’s website at www.Moxian.com

Let us hear your thoughts: Moxian, Inc. Message Board

In a recent article on the Jewish Journal website (http://dtn.fm/DhxK8), doctors, dignitaries and officials representing Israel and California convened at Cedars-Sinai Medical Center on February 8, 2016, to witness the signing of an agreement between Israel’s Ministry of Science and the California Institute for Regenerative Medicine (CIRM) to collaborate on stem cell research. It follows a 2014 Memorandum of Understanding to promote collaboration and innovation between Israel and California.

“Stem cell research is a cutting-edge field full of promise and opportunity. Who better to forge new ground together than the State of Israel and the State of California?” Israeli Minister of Science, Technology and Space Ofir Akunis said in the article. “Both are hotbeds of innovation, medical research and technological invention and have a strong commitment to science as a means to improve the lot of all humanity … creating a brighter future for us all.”

International Stem Cell Corp. (OTCQB: ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. The company’s stem cells present superior immune matching capabilities and can be used in millions of people, regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

Stem cells are the future of medicine. Companies like International Stem Cell Corp. are on the front lines of this invaluable research, constantly looking for new ways stem cells can improve our quality of life by treating and eliminating diseases of the central nervous system (i.e. Parkinson’s disease), the liver, and the eye. The technology is getting better every day, and more people are coming around to at least giving it a look. The company has an ethical and moral purpose along with the potential to capitalize on a huge revenue stream.

The combined direct and indirect costs of Parkinson’s disease (PD), including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the U.S. alone. Medication costs for an individual person with PD average $2,500 a year, and therapeutic surgery can cost up to $100,000 dollars per patient.

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board

Whether in the kitchen or on the go, Content Checked Holdings, Inc. (OTCQB: CNCK) is empowering individuals and families and enhancing their quality of life. A rising software developer, Content Checked has created a series of reliable, efficient and fast mobile apps that assist consumers in making informed food purchasing decisions based on their dietary preferences and restrictions.

All three of Content Checked’s apps serve as easy, real-time shopping tools that target the food allergy and intolerances market, which was valued at approximately US$13 billion in 2015. Across ContentChecked, SugarChecked and MigraineChecked, the company offers complementary solutions to consumers dealing with food allergies and sensitivities. With these apps, Content Checked goes beyond the label, allowing consumers to better understand food labels and ingredients, which are often ambiguous or disingenuous. While they shop in real time, users also receive suggestions for healthier alternative food products to those that do not match their dietary settings.

Families with food allergies are at the center of the “food as wellness” movement. For the 15 million-plus Americans suffering from food allergies, the 38 million suffering from migraines and chronic headaches and the 60 million-plus dealing with food sensitivities, Content Checked offers a solution to address their restrictions and concerns. The company has created a vast database of allergens, triggers and ingredients that correlate to 16 food allergies and intolerances, four types of sugar, and migraines or chronic headaches. This robust database of nutritional and ingredient information is updated 24/7 and currently covers more than 300,000 packaged food products available for sale and distribution in the United States. ContentChecked and MigraineChecked are the first applications with wide-ranging, accurate, and in-depth allergen and migraine definitions for over 70% of conventional U.S. food products.

Content Checked’s database gives users access to a comprehensive platform that allows them to cross-check the ingredients in packaged goods and recipes for hidden allergens and migraine triggers. The company is not only teaching consumers about the fixings in their foods and packaged goods, it is also inspiring them to take steps to cook wisely.

For more information, visit www.contentchecked.com

Let us hear your thoughts: ContentChecked Holdings Inc. Message Board

Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced the appointment of two new members to its board of directors: Dr. Clifford A. Selsky and Paul Akin. Akin brings a wealth of financial experience developed across his prior operating and board roles to the Immune Therapeutics board, while Selsky offers a critical perspective as a scientist, physician and patient advocate. The company will look to leverage this combined experience as it continues to pursue sustainable financial growth by developing and commercializing novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, particularly in emerging global markets.

“Paul Akin and Dr. Selsky’s breadth of knowledge and experience will provide invaluable insight to Immune as we continue to grow the business and strive to deliver innovative therapies in emerging nations,” Noreen Griffin, chief executive officer of Immune Therapeutics, stated in this morning’s news release.

The release went on to provide additional background information on the company’s new board members.

Paul Akin brings more than 25 years of leadership experience to the Immune Therapeutics board. In addition to serving as a significant investor and active strategist for the company, he has played an instrumental role in the strategic planning and coordination of market penetration, expansion and capitalization. Akin currently serves as the CEO and executive chairman of San Francisco-based Collier Warehouse Group, which has, during his tenure, recorded annual double-digit growth rates. Akin is also an active investor in a variety of emerging growth companies and has served in a number of business roles – including executive chairman, independent board director, strategic advisor, venture capital limited partner, market pundit, private investor and trustee.

Clifford A. Selsky, PhD, MD, has worked as a practicing pediatrician for the past 20 years. He earned his PhD in microbiology and molecular genetics at the University of Miami School of Medicine before completing DNA repair research studies at Harvard School of Public Health and Stanford University. After training in pediatrics at Yale New Haven Hospital and completing a pediatric hematology and oncology fellowship at Yale University School of Medicine, Selsky founded the Children’s Center of Cancer and Blood Disease at the Florida Hospital Cancer Institute. Currently, he is a pediatrician at Family First Pediatrics, which he established in 2013.

Immune Therapeutics, Inc. is a biotechnology company with a promising portfolio of products and immunotherapy technologies designed to harness the power of the immune system in order to enhance the treatment of cancer, infections such as HIV/Aids, chronic inflammatory diseases and autoimmune diseases. The company is currently pursuing investigations of its most advanced clinical programs – including met-enkephalin (MENK) and low dose naltrexone (LDN), or Lodonal™ – as viable treatments for a variety of underserved indications.

Learn more by visiting www.immunetherapeutics.com

Let us hear your thoughts: Immune Therapeutics, Inc. Message Board